SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-218096
Filing Date
2022-08-11
Accepted
2022-08-11 09:10:56
Documents
14
Period of Report
2022-08-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d388911d8k.htm   iXBRL 8-K 26968
2 EX-99.1 d388911dex991.htm EX-99.1 12758
6 GRAPHIC g388911g0811005344686.jpg GRAPHIC 2278
  Complete submission text file 0001193125-22-218096.txt   171007

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA virx-20220810.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE virx-20220810_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE virx-20220810_pre.xml EX-101.PRE 11254
8 EXTRACTED XBRL INSTANCE DOCUMENT d388911d8k_htm.xml XML 3346
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 221154003
SIC: 2834 Pharmaceutical Preparations